摘要
静脉血栓栓塞（VTE）是第三大常见的心血管疾病，其发病机制尚未明确。传统的诊断方法在VTE诊断、监测和预后方面效果不佳。MicroRNA（miRNA）是一类参与基因转录后调控的非编码小RNA，在疾病的发生和发展中发挥着重要作用。循环miRNA稳定存在于血浆、血清以及其他体液中，其在心血管疾病、恶性肿瘤以及VTE中有望成为新的生物标志物。此综述以miRNA生物合成及循环miRNA的起源为出发点，总结了循环miRNA作为VTE诊断标志物的最新进展，并指出循环miRNA在VTE临床应用的挑战和前景。
Venous thromboembolism （VTE） remains the third most common cardiovascular disease with a vague pathogenesis. Conventional biomarkers exhibit poor performance in the diagnosis, surveillance and prognosis of VTE. MicroRNAs （ miRNAs ） are a class of evolutionarily conserved small non-coding RNAs that are involved in the regulation of gene expression and protein translation An array of experimental studies has shown the importance of miRNAs for disease initiation/progression. Circulating miRNAs are found in plasma, serum and other body fluids in an apparently stable form. Reeent evidence revealed that circulating miRNAs, a novel family of regulatory molecules, emerge as a promising class of biomarkers in many eardiovascular diseases, malignaneies as well as VTE. This review describes current understanding of miRNA biogenesis and the origins and types of circulating miRNAs and gives an outline of recent work on circulating miRNAs as well as its challenges and perspectives of the clinical utility of circulating miRNA in VTE.
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2016年第10期791-794,共4页
Chinese Journal of Laboratory Medicine
